Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HT008
- Development stage
- Unknown
- Lead developer
- NeuMed Biotechnology
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
HT008 is a standardized botanical extract developed by Neumed for the improvement of joint health and the management of osteoarthritis symptoms. It is a complex mixture derived from three medicinal herbs: *Eleutherococcus senticosus* (Siberian ginseng), *Achyranthes bidentata*, and *Phlomis umbrosa*. The extract exerts its therapeutic effects through multiple anti-inflammatory and chondroprotective pathways. Specifically, it inhibits the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2) and cytokines including interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). Furthermore, HT008 helps preserve joint integrity by suppressing the expression of matrix metalloproteinases (MMPs), such as MMP-1, MMP-3, and MMP-13, which are responsible for the degradation of the articular cartilage extracellular matrix. In South Korea, HT008 has been recognized by the Ministry of Food and Drug Safety (MFDS) as a functional ingredient for joint health.
- Other names
- Eleutherococcus senticosus, Achyranthes bidentata, and Phlomis umbrosa extract
02
Targets
IL1B (Interleukin-1 beta)MMP1 (Matrix metalloproteinase-1)MMP13 (Matrix metalloproteinase-13)MMP3 (Matrix metalloproteinase-3)PGE2 (Prostaglandin E2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on HT008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HT008.